Литвинов Виталий Ильич – научный руководитель ГБУЗ «Московский городской научно-практический центр борьбы
с туберкулезом Департамента здравоохранения города Москвы», доктор медицинских наук, профессор, академик РАН
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. + 7 (495) 268-04-15
e-mail: mnpcbtlv@yandex.ru
1. Борисов С.Е., Лукина Г.В., Слогоцкая Л.В. и др. Скрининг и мониторинг туберкулезной инфекции у ревматологических больных, получающих
генно-инженерные биологические препараты // Туберкулез и болезни легких. – 2011. – № 6 – С. 42-50.
2. Ванеева Т.В., Куликовская Н.В., Краснова М.А. и др. Результаты применения иммунологических методов диагностики туберкулеза in vivo и
in vitro у больных ВИЧ-инфекцией // Туберкулез и социально значимые заболевания. – 2016. – № 2. – С. 66-71.
3. Кожная проба с препаратом «ДИАСКИНТЕСТ» – новые возможности идентификации туберкулезной инфекции / под ред. М.И. Пальцева. –
М.: ШИКО, 2011. – 256 с.
4. Литвинов В.И. Латентная туберкулезная инфекция – миф или реальность? // Туберкулез и болезни легких. – 2011. – № 6. – С. 3-9.
5. Литвинов В.И. Латентная туберкулезная инфекция: свойства возбудителя; реакция макроорганизма; эпидемиология и диагностика
(IGRA-тесты, ДИАСКИНТЕСТ® и другие подходы), лечение. – М.: МНПЦБТ, 2016. – 194 с.
6. Литвинов В.И. «Дремлющие» микобактерии, дормантные локусы, латентная туберкулезная инфекция // Туберкулез и социально значимые
заболевания. – 2016. – № 2. – С. 5-13.
7. Скворцов Т.А., Ажикина Т.Л. Адаптивные изменения экспрессии генов Mycobacterium tuberculosis в ходе инфекционного процесса //
Биоорг. химия. – 2012. – Т. 38. – С. 391-405.
8. Слогоцкая Л.B., Кочетков Я.А., Сенчихина О.Ю. Эффективность нового кожного теста (Диаскинтест) при выявлении инфицированных и
заболевших подростков среди контактировавших с больными туберкулезом // Вопр. соврем. педиатрии. – 2011. – Т. 10. – № 3. – С. 70-75.
9. Слогоцкая Л.В., Иванова Д.А., Сенчихина О.Ю. и др. Сравнительное исследование результатов кожного теста с аллергеном туберкулезным
рекомбинантным и лабораторного теста QuantiFERON-GIT у детей и подростков с туберкулезной инфекцией // Туберкулез и социальнозначимые заболевания. – 2013. – № 2. – С. 45-50.
10. Слогоцкая Л.В., Сенчихина О.Ю., Никитина Г.В., Богородская Е.М. Эффективность кожного теста с аллергеном туберкулезным
рекомбинантным при выявлении туберкулеза у детей и подростков Москвы в 2013 г. // Педиатр. фармакология. – 2015. – № 1. – С. 99-103.
11. Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection // Clin. Dev. Immunol. – 2011. – P. 814-943.
12. Ai J., Ruan Q., Liu Q., Zhang W. Updates on the risk factors for latent tuberculosis reactivation and their managements // Emerg. Microbes. Infect. – 2016. –
Vol. 5. – e 10.
13. Al-Orainey I. Diagnosis of latent tuberculosis: Can we do better? // Ann. Thorac. Med. – 2009. – Vol. 4. – N. 1. – P. 5-9.
14. Alsdurf H., Hill P., Matteelli A. et al. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis //
Lancet. Infect. Dis. – 2016. – Vol. 16. – N. 11. – P. 1269-1278.
15. Auguste P., Tsertsvadze A., Court R. et al. A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent
tuberculosis in high-risk groups // Tuberculosis (Edinb). – 2016. – Vol. 99. – P. 81-91.
16. Barry C., Boshoff H., Dartois V. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies // Nat. Rev. Microbiol. – 2009. –
Vol. 7. – N. 12. – P. 845–855.
17. Bibbins-Domingo K., Grossman D., Curry S. et al. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force Recommendation
statement // J. Amer. med. Ass. – 2016. – Vol. 316. – N. 9. – P. 962-969.
18. Cardona P. A dynamic reinfection hypothesis of latent tuberculosis infection // Infection. – 2009. – Vol. 37. – P. 80-86.
19. Casey R., Blumenkrantz D., Millington K. et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden
in tuberculosis // PLoSOne. – 2010. – Vol. 5. – N. 12. – e15619.
20. Chee C., KhinMar K., Gan S. et al. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens //
Am. J. Respir. Crit. Care Med. – 2007. – Vol. 175. – N. 3. – P. 282-287.
21. Commandeur S., van Meijgaarden K., Prins C. An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens
targeted by human T cells expressed during pulmonary infection // J. Immunol. – 2013. – Vol. 190. – N. 4. – P. 1659-1671.
22. Diel R., Goletti D., Ferrara G. et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and
meta-analysis // Eur. Respir. J. – 2011(a). – Vol. 37. – N. 1. – P. 88-99.
23. Diel R., Loddenkemper R., Niemann S. et al. Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active
tuberculosis: an update // Am. J. Respir. Crit. Care Med. – 2011(b). – Vol. 183. – P. 88–95.
24. Ernst J. The immunological life cycle of tuberculosis // Nat. Rev. Immunol. – 2012. – Vol. 12. – N. 8. – P. 581-591.
25. Fox G., Dobler C., Marais B., Denholm J. Preventive therapy for latent tuberculosis infection-the promise and the challenges // Int. J. Infect. Dis. – 2016. –
Vol. 9712 – N. 16. – P. 31223-31231.
26. Higuchi K., Harada N., Fukazawa K. et al. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis // Tuberculosis
(Edinb.). – 2008. – Vol. 88. – N. 3. – P. 244-248.
27. Kahwati L., Feltner C., Halpern M. et al. Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic
review for the US Preventive Services Task Force // J. Amer. med. Ass. – 2016. – Vol. 316. – N. 9. – P. 970-83.
28. Kuhnath-Velayudhan S., Gennaro M. Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery // Clin. Microbiol. Rev. – 2011. – Vol. 24. –
N. 4. – P. 792-805.
29. Lin M., Ottenhoff T. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention //
Endocr. Metab. Immune Disord. Drug Targets. – 2008. – Vol. 8. – P. 15-29.30. Lin P., Rodgers M., Smith L. et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model //
Infection and Immunity. – 2009. – Vol. 77. – N. 10. – P. 4631-4642.
31. Mack U., Migliori G., Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement //
Eur. Respir. J. – 2009. – Vol. 33. – P. 956-973.
32. Mazurek G., Jereb J., Vernon A. et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection //
MMWR Recomm. Rep. – 2010. – Vol. 59. – P. 1-25.
33. Millington K., Innes J., Hackforth S. et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cell and
antigen load // J. Immunol. – 2007. – Vol. 178. – N. 8. – P. 5217-5226.
34. Mori T., Sakatani M., Yamagishi F. et al. Specific detection of tuberculosis infection: An interferon-gamma-based assay using new antigens // Am. J. Respir.
Crit. Care Med. – 2004. – Vol. 170. – P. 59-64.
35. Mulder C., van Deutekom H., Huisman E. et al. Role of the Quanti-FERON(R)-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection //
Eur. Respir. J. – 2012. – Vol. 40. – N. 6. – P. 1443-1449.
36. Pai M., O’Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects // Semin. Respir. Crit. Care Med. – 2008(a). –
Vol. 29. – P. 560-568.
37. Pai M., Zwerling A., Menzies D. Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update // Ann. Intern. Med. –
2008(b). – Vol. 149. – N. 3. – P. 177-184.
38. Park H., Guinn K., Harrell M. et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis //
Mol. Microbiol. – 2003. – Vol. 48. – P. 833-843.
39. Petruccioli E., Scriba T., Petrone L. et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis // Eur. Respir. J. – 2016. –
Vol. 48. – N. 6. – P. 1751-1763.
40. Rangaka M., Wilkinson K., Glynn J. et al. Predictive value of interferon-γ release assay for incident active tuberculosis: a systematic review and
meta-analysis // Lancet Infect. Dis. – 2012. – Vol. 12. – N. 1. – P. 45-55.
41. Ravn P., Munk M., Andersen A. et al. Prospective evaluation of a whole blood test using Mycobacterium tuberculosis specific antigen ESAT-6 and CFP10
for diagnosis of active tuberculosis // Clin. Diagn. Labor. Immunol. – 2005. – Vol. 12. – N. 4. – P. 491-496.
42. Roth P., Grim S., Gallitano S. et al. Serial testing for latent tuberculosis infection in transplant candidates: a retrospective review // Transpl. Infect. Dis. –
2016. – Vol. 18. – N. 1. – P. 14-21.
43. Ruan Q., Zhang S., Ai J. et al. Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and
meta-analysis // Clin. Rheumatol. – 2016. – Vol. 35. – N. 2. – P. 417-425.
44. Rustad T., Harrell M., Liao R., Sherman D. The enduring hypoxic response of Mycobacterium tuberculosis // PLoS. One. – 2008. – Vol. 3. – N. 1. – e1502.
45. Sandgren A., Vonk Noordegraaf-Schouten M., van Kessel F. et al. Initiation and completion rates for latent tuberculosis infection treatment: a systematic
review // BMC Infect. Dis. – 2016. – Vol. 16. – P. 204.
46. Sargentini V., Mariotti S., Carrara S. et al Cytometric detection of antigen-specific INF-gamma/IL-2 secreting cells in the diagnosis of tuberculosis //
BMC Infect. Dis. – 2009. – Vol. 9. – P. 99.
47. Serra-Vidal M., Latorre I., Franken K. et al. Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis // Front. Microbiol. –
2014. – Vol. 5. – P. 517.
48. Sester M., Sotqiu G., Lanqe C. et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis //
Eur. Respir. J. – 2011. – Vol. 37. – N. 1. – P. 100-111.
49. Sharma S., Sharma A., Kadhiravan T., Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis
in HIV-negative people at risk of active TB // Evid. Based. Child. Health. – 2014. – Vol. 9. – N. 1. – P. 169-294.
50. Stuurman A., Vonk Noordegraaf-Schouten M., van Kessel F. et al. Interventions for improving adherence to treatment for latent tuberculosis infection:
a systematic review // BMC Infect. Dis. – 2016. – Vol. 16. – P. 257.
51. Turetz M., Ma K. Diagnosis and management of latent tuberculosis // Curr. Opin. Infect. Dis. – 2016. – Vol. 29. – N. 2. – P. 205-211.
52. Vekemans J., Lienhardt C., Sillah J. et al. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community
controls in The Gambia // Infect. Immun. – 2001. – Vol. 69. – N. 10. – P. 6554-6557.
53. Wallis R., Pai M., Menzies D. et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice // Lancet. – 2010. – Vol. 375. –
P. 1920-1937.
54. Wong S., Gao Q., Tsoi K. et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients
with autoimmune diseases: a systematic review and meta-analysis // Thorax. – 2016. – Vol. 71. – N. 1. – P. 64-72.
